Efficacy and safety of sacubitril/valsartan in the treatment of atrial fibrillation after ablation: a Meta-analysis

Abstract

Objective To systematically evaluate the efficacy and safety of sacubitril/valsartan (SV) in the treatment of atrial fibrillation(AF).Methods Computerized searches of PubMed, Embase, Web of Science, The Cochrane Library, CNKI, WanFang Data and VIP from the time of inception to April 27, 2024 were conducted. Literature screening, data extraction and quality assessment were conducted independently by two researchers. Meta-analysis was performed using RevMan 5.4 software.Results A total of 10 studies were included, including 8 randomized controlled trials, 2 cohort studies, with a cumulative total of 1 355 patients. The test group was treated with conventional therapy+SV, and the control group was treated with conventional therapy or conventional therapy+angiotensin converting enzyme inhibitor (ACEI)/angiotensin receptor blockers (ARB). The results of the Meta-analysis showed that in patients with AF who converted to sinus rhythm after undergoing radiofrequency catheter ablation, compared with the conventional therapy+ACEI/ARB, the conventional therapy+SV was able to significantly reduce the recurrence rate of AF [OR=0.35, 95%CI(0.26, 0.46), P

Keywords

• sacubitril/valsartan
• atrial fibrillation
• angiotensin converting enzyme inhibitors
• angiotensin receptor blockers
• ablation
• meta-analysis